Semaglutide vs. Tirzepatide – Mechanism, Dosing, and Key Differences
Comparing semaglutide and tirzepatide? See how these two GLP-1 medications differ in mechanism, dosing, side effects, and cost. Semaglutide activates one receptor; tirzepatide activates two. Both are once-weekly injections. Both are tracked in MeAgain — so whatever your health partner prescribes, the app is ready.
Last updated March 2026
Tracking Either Medication in MeAgain
Side-by-Side Dose Tracking for Both Medications
Semaglutide and tirzepatide have different titration schedules, different dose units, and different pen or vial formats. MeAgain’s injection tracker supports custom dose logging for both — whether you’re on brand pens or compounded vials, the shot day checklist and medication levels chart work for either.
Estimated Medication Levels for Both GLP-1s
Semaglutide has a 7-day half-life; tirzepatide has a 5-day half-life. MeAgain’s pharmacokinetic curve adjusts to your current medication so you can see estimated levels between doses — whether you’re on semaglutide or tirzepatide.
Nutrition and Side Effects, Regardless of Which Molecule
Both medications suppress appetite and produce similar GI side effect profiles. Five food logging methods and a side effect tracker with severity ratings work identically whether you’re on semaglutide or tirzepatide — log protein, water, fiber, and symptoms in one place.
Semaglutide vs. Tirzepatide: Head-to-Head Comparison
Semaglutide and tirzepatide are both once-weekly injectable medications used for weight management, but they work through different mechanisms and have different clinical profiles. Understanding the key differences can help you have a more informed conversation with your health partner.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Half-life | ~7 days | ~5 days |
| Max dose (weight) | 2.4mg (Wegovy) | 15mg (Zepbound) |
| Injection frequency | Once weekly | Once weekly |
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro |
| FDA weight indication | Wegovy (2021) | Zepbound (2023) |
| FDA T2D indication | Ozempic (2017) | Mounjaro (2022) |
| Brand cost (list price) | $1,000–1,500/mo | $1,000+/mo |
| MeAgain compounded | $123/mo | $199/mo |
Which Is Right for You? A Decision Framework
- Both are once-weekly injections — the administration routine is nearly identical
- Tirzepatide’s dual mechanism produced greater average weight loss in clinical trials; individual results vary
- Side effect profiles are similar (nausea, constipation, fatigue) — neither is clearly easier to tolerate
- Your health history, other medications, and insurance situation matter more than clinical averages
- Cost without insurance: MeAgain offers semaglutide at $123/mo and tirzepatide at $199/mo (zero markup)
- This is a clinical decision — your health partner should guide which molecule is right for you
MeAgain tracks both semaglutide and tirzepatide. Whatever your health partner prescribes, the shot day checklist, estimated medication levels, nutrition logging, and side effect tracker are all ready to use.
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.
One App for Any GLP-1 Medication
Switch Medications Without Losing Your Data
If your health partner switches you from semaglutide to tirzepatide — or vice versa — your full history of injections, side effects, nutrition, and weight stays intact in MeAgain. Your log doesn’t restart when your medication changes; your journey continues.
Pharmacokinetic Curves Adjusted to Your Molecule
Semaglutide has a 7-day half-life; tirzepatide has a 5-day half-life. MeAgain’s estimated medication levels chart adjusts to whichever molecule you’re on so you always see an accurate curve for your current medication — not a generic GLP-1 estimate.
Compounded Options for Both Molecules
MeAgain offers both compounded semaglutide ($123/mo) and compounded tirzepatide ($199/mo) at zero markup for subscribers. The same app you use to track your medication can source it — without the $1,000+ brand price tag.
What Subscribers Say About Switching Between GLP-1 Medications
The Molecule May Change. The Journey Continues.
Some MeAgain subscribers have switched from semaglutide to tirzepatide as their health partner optimized their treatment. Having a complete history of injections, side effects, and weight in one place made the transition smoother — no starting from scratch, no losing context.
Both semaglutide and tirzepatide are long-term medications. The most important thing isn’t which molecule you start with — it’s having the tracking infrastructure to see how your body responds over time. MeAgain gives you that, regardless of which medication you’re on.
What Our Users Say
Semaglutide vs. Tirzepatide — Your Questions Answered
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two receptors (GLP-1 and GIP). Both are once-weekly injections used for weight management, with similar side effect profiles. Tirzepatide produced greater average weight loss in clinical trials, but individual responses vary. Your health partner should guide your choice.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.